India Immuno-Oncology Drugs Market Is Estimated To Witness High Growth Owing To Rising Oncology Development Programs
Immuno-oncology drugs such as drugs for treating breast cancer, lung cancer, melanoma and blood cancers are gaining popularity in India. Immuno-oncology drugs help enhance the body's natural defenses to fight against cancer by leveraging the power of the patient's own immune system. These innovative drugs are more effective with fewer side effects compared to traditional cancer treatments. The rising burden of cancer in India has increased demand for new targeted and personalized treatment options which is driving research and development of novel immuno-oncology drugs in the country.
The global India Immuno-Oncology Drugs Market is estimated to be valued at US$ 338.98 Mn in 2023 and is expected to exhibit a CAGR of 4.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Opportunity:
Rising Oncology Development Programs
The opportunity for growth of immuno-oncology drugs market in India lies in the rising number of oncology development programs by pharmaceutical companies and hospitals. Major players have increased focus on clinical trials and research collaborations for developing novel immunotherapies for cancer treatment. For instance, AstraZeneca has ongoing 50+ oncology clinical trials in India exploring new immunotherapies for lung, breast and gastric cancers. Hospitals are also conducting immuno-oncology programs in partnership with global drugmakers to test international immune-modulating drugs on Indian cancer patients. The proliferating oncology development programs will give access to a wider range of immuno-oncology treatment options for patients in India, thereby driving the market growth over the forecast period.
Porter's Analysis
Threat of new entrants: The Indian immuno-oncology drugs market has moderate threat of new entrants due to the presence of stringent regulations for new players and high capital requirements for R&D.
Bargaining power of buyers: Individual buyers have relatively low bargaining power due to availability of limited treatment options whereas large pharmacy chains have moderate bargaining power due to the availability of substitutes.
Bargaining power of suppliers: Key raw material suppliers have moderate bargaining power due to the availability of substitutes and intellectual property rights of end product companies.
Threat of new substitutes: The threat of substitutes is moderate as other cancer treatment options like chemotherapy and targeted therapy are available.
Competitive rivalry: The competition is high amongst existing players to gain maximum market share.
SWOT Analysis
Strength: Growing prevalence of cancer in India, increasing healthcare expenditure, favorable government initiatives.
Weakness: High treatment cost, lack of awareness.
Opportunity: Rising population, scope for development of combination therapies.
Threats: Patent expiries of blockbuster drugs, entry of biosimilars.
Key Takeaways
The India India Immuno-Oncology Drugs Market Growth is expected to witness high growth fueled by the growing cancer burden and rising healthcare expenditure in the country. The global India Immuno-Oncology Drugs Market is estimated to be valued at US$ 338.98 Mn in 2023 and is expected to exhibit a CAGR of 4.2% over the forecast period 2023 to 2030.
The Southern region currently dominates the market due to presence of major players and advanced healthcare infrastructure. Key players operating in the India immuno-oncology drugs market are Fort Dearborn, Multi Color Corporation, and Mondi Group.
The government is undertaking various initiatives like launching National Cancer Grid to reduce the treatment cost and increase awareness. However, the high cost of innovative therapies continues to remain a major challenge for widespread adoption. Development of affordable combination therapies through strategic partnerships is expected to provide new growth opportunities in the forecast period.
Patent expiries of blockbuster drugs and entry of biosimilars may increase treatment options but also intensify competition. Overall, increasing healthcare access and focus on cancer screening and prevention programs are projected to drive the demand for immuno-oncology therapies in India.
Check below related articles on this topic: https://www.newsanalyticspro.com/the-immuno-oncology-drugs-market-in-india-is-driven-by-rising-cancer/